Dzinamarira Tafadzwa, Tungwarara Nigel, Chitungo Itai, Chimene Munashe, Iradukunda Patrick Gad, Mashora Moreblessing, Murewanhema Grant, Rwibasira Gallican Nshogoza, Musuka Godfrey
School of Health Systems & Public Health, University of Pretoria, Pretoria 0002, South Africa.
ICAP, Columbia University, Harare P.O. Box MP167, Zimbabwe.
Vaccines (Basel). 2022 Feb 7;10(2):252. doi: 10.3390/vaccines10020252.
Despite an array of preventive global public health interventions, SARS-CoV-2 has continued to spread significantly, infecting millions of people across the globe weekly. Newer variants of interest and concern have continued to emerge, placing the need for policymakers to rethink prevention strategies to end the pandemic. The approval of SARS-CoV-2 vaccines for public health use in December 2020 was seen as a significant development towards pandemic control and possibly ending the pandemic. However, breakthrough infections have continued to be observed among the 'fully vaccinated', and the duration and sustainability of vaccine-induced immunity has remained a topical public health discourse. In the absence of accurate public health communication, the breakthrough infections and waning immunity concepts have potential to further compound vaccine hesitancy. With this viewpoint, we discuss breakthrough SARS-CoV-2 infections, waning immunity, the need for COVID-19 booster shots, vaccine inequities, and the need to address vaccine hesitancy adequately to propel global vaccination programs forward.
尽管采取了一系列全球性的公共卫生预防干预措施，但严重急性呼吸综合征冠状病毒2（SARS-CoV-2）仍在持续大幅传播，每周感染全球数百万人。值得关注的新型变异毒株不断出现，这使得政策制定者有必要重新思考预防策略以终结这一疫情大流行。2020年12月SARS-CoV-2疫苗获批用于公共卫生领域，这被视为在控制疫情大流行以及可能终结疫情方面取得的一项重大进展。然而，在“完全接种疫苗者”中仍不断观察到突破性感染情况，并且疫苗诱导免疫的持续时间和可持续性仍是一个热门的公共卫生话题。在缺乏准确的公共卫生宣传的情况下，突破性感染和免疫减弱的概念有可能进一步加剧疫苗犹豫现象。基于这一观点，我们将讨论SARS-CoV-2突破性感染、免疫减弱、新冠病毒加强针的必要性、疫苗不平等问题，以及充分解决疫苗犹豫现象以推动全球疫苗接种计划向前发展的必要性。
